Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CDR132L in heart failure with preserved ejection fraction and left ventricular hypertrophy
2024-515796-35-00Phase 2Authorised
- Sponsor
- Novo Nordisk
- Start
- May 2025
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 9
01
Overview
Phase 2, randomised, double-blind trial of CDR132L in heart failure with preserved ejection fraction (HFpEF) and left ventricular hypertrophy (LVH) (3 arms), sponsored by Novo Nordisk. Primary endpoint: Change in normalised miR-132 from baseline to week 24. Planned start May 2025; status: authorised.
02
Drugs
CDR132L
03
Conditions
heart failure with preserved ejection fraction (HFpEF)left ventricular hypertrophy (LVH)
Beyond the preview
Go deeper on 2024-515796-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515796-35-00.